What You Need to Know Before Starting Your Practice: A Focus on Retinal Vein Occlusion
Supported by an educational grant from Regeneron Pharmaceuticals Inc.
This activity is jointly povided by


OVERVIEW
Treatment of patients with retinal vein occlusion (RVO) continues to evolve, with the emergence of new data and new diagnostic techniques. This leads to many questions for retina fellows contemplating the completion of their training and entering retina practice. This interactive, online, question-driven, video panel discussion between lead faculty and second-year retina fellows will provide participants with the opportunity to consider the efficacy and safety of available therapies, the use of emerging diagnostic techniques, and optimal treatment plans for patients.
Target Audience
The goal of this activity is to provide retina fellows and practicing retina specialists with the most up-to-date clinical knowledge and strategies for the optimal treatment and management of patients with RVO.
Learning Objectives
After completing this activity, the participant should be better able to:
- DESCRIBE various principles of retina practice management.
- EVALUATE the latest clinical data for the treatment of RVO.
- COMPARE the effect of dosing strategies on the efficacy and safety of current and emerging therapies for the management of RVO.
Quan Dong Nguyen, MD, MSc (Co-Chair)
Omaha, Nebraska
Diana V. Do, MD (Co-Chair)
Omaha, Nebraska
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Faculty/Presenters
Name of Faculty or Presenter | Reported Financial Relationship |
David S. Boyer, MD | Served on a speakers’ bureau for Allergan Inc and Alcon; is a stockholder/shareholder in Allegro Ophthalmics LLC, Neurotech Pharmaceuticals Inc, OHR Pharmaceutical Inc, and Ophthotech Corporation; served as a consultant/independent contractor for Aerpio Therapeutics, Alcon, Alimera Sciences, Allegro Ophthalmics LLC, Allergan Inc, Bausch & Lomb Incorporated, Bayer, Boehringer Ingelheim GmbH, CoDa Therapeutics Inc, Foresite Biotherapeutics Inc, Genentech Inc, GenSite Biologics, Graybug Vision Inc, GlaxoSmithKline, Neurotech Pharmaceuticals Inc, Notal Vision Inc, Novartis, OHR Pharmaceutical Inc, Ophthotech Corporation, Optos, Regeneron Pharmaceuticals Inc, RetroSense Therapeutics, Regulus Therapeutics Inc, StemCells Inc, Sun Pharmaceutical Industries Inc, and ThromboGenics. |
Darius M. Moshfeghi, MD | Received grant/research support from ThromboGenics; served as a consultant/independent contractor for Alcon, Genentech Inc, Iconic Therapeutics Inc, InSitu Therapeutics Inc, and Synergetics; and, is a stockholder/shareholder in: Grand Legend Technology. |
Carl D. Regillo, MD, FACS | Received grant/research support from and served as a consultant/independent contractor for Alcon, Allergan Inc, Genentech Inc and Iconic Therapeutics Inc; received grant/research support from Iconic Therapeutics Inc and Regeneron Pharmaceuticals Inc; and served as a consultant/independent contractor for Bayer and Allegro Ophthalmics LLC. |
Christina Y. Weng, MD, MBA | Nothing to disclose |
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Planners/Managers
Name of Planner or Manager | Reported Financial Relationship |
Quan Dong Nguyen, MD, MSc | Received grant/research support from and served as a consultant/independent contractor for Genentech Inc, Regeneron Pharmaceuticals Inc, and Santen Pharmaceutical Co Ltd; and received grant/research support from Novartis. |
Diana V. Do, MD | Received grant/research support from and served as a consultant/independent contractor for Genentech Inc and Regeneron Pharmaceuticals Inc; received grant/research support from Novartis; and served as a consultant/independent contractor for Allergan Inc. |
Christina M. Ohnsman, MD | Nothing to disclose |
Andrea Funk | Nothing to disclose |
Laura Gilsdorf | Nothing to disclose |
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and ASiM do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Available Credit
- 0.50 AMA PRA Category 1 Credit(s)™
Accreditation Period
Required Hardware/software
System Requirements
PC | MAC |
*Required to view printable (PDF) version of the lesson. |